Marksans Pharma Limited (MARKSANS.NS)
Marksans Pharma Limited operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Mumbai, MA, IN. The stock last traded at $333.00, up 9.76% on the session, giving a market capitalisation of $150.90B. Its beta of 1.12 implies it has historically moved more than the broad market.
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Marksans Pharma Limited is most often compared with the following Healthcare names: